Innovative Retina Treatments Showcased by Outlook Therapeutics
ISELIN, N.J. — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical leader committed to improving the treatment landscape for retinal diseases, has exciting news. The company has announced its participation in the annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase, scheduled for July 29, 2025. This prestigious event will take place in Long Beach, California, and will focus on breakthroughs in treating ocular conditions.
Event Details and Anticipation
During the event, attendees can expect to see innovations that could potentially change the way retinal diseases are treated. Bob Jahr, the Chief Executive Officer of Outlook Therapeutics, will represent the company in the Innovation Showcase. The presentation is set for the morning of July 29, from 8:35 to 9:35 AM PT. This session will offer an in-depth look at the company’s cutting-edge research and development initiatives.
About the Innovation Summit
The Ophthalmology Innovation Summit has been an essential venue since its inception in 2009, aimed at unveiling novel therapies that address critical issues in ophthalmic diseases. The summit connects entrepreneurs, clinical leaders, and industry experts, facilitating collaboration and advancements in the field of ocular health.
Focus on ONS-5010/LYTENAVA™
At the heart of Outlook Therapeutics’ mission is ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), an ophthalmic formulation designed to enhance the standard of care in treating retinal diseases. This innovative treatment has received Marketing Authorization from the European Commission and MHRA for the treatment of wet age-related macular degeneration (AMD), marking a significant milestone for both the company and healthcare providers.
Commercial Launch and Aspirations
Outlook Therapeutics has successfully commenced the commercial launch of LYTENAVA™ in Germany and the UK, presenting this groundbreaking treatment to those suffering from wet AMD. In the United States, the company is gearing up for the potential approval of ONS-5010/LYTENAVA™, as a Biologics License Application (BLA) has been resubmitted to the FDA. If the FDA approves this product, it would become the first ophthalmic formulation of bevacizumab available for retinal indications.
Investor Relations and Company Contact
As Outlook Therapeutics continues its journey towards innovative treatments, investor inquiries can be directed to Jenene Thomas, Chief Executive Officer at JTC Team, LLC. They can be reached at 908.824.0775 or via the provided email address. The company welcomes discussions from interested parties as it forges ahead in developing therapies that target critical needs in ocular health.
Frequently Asked Questions
What is ONS-5010/LYTENAVA™?
ONS-5010/LYTENAVA™ is an innovative ophthalmic formulation of bevacizumab aimed at treating retinal diseases, specifically wet AMD.
Where will Outlook Therapeutics present its innovations?
Outlook Therapeutics will present at the Ophthalmology Innovation Summit in Long Beach, California.
Who is the presenter at the event?
Bob Jahr, the Chief Executive Officer of Outlook Therapeutics, will be presenting during the Innovation Showcase.
What significant milestone has LYTENAVA™ achieved?
LYTENAVA™ has received Marketing Authorization for the treatment of wet AMD from the European Commission and MHRA.
What are the future plans of Outlook Therapeutics?
The company aims to gain FDA approval for ONS-5010/LYTENAVA™, which would be the first approved formulation of its kind for retinal indications in the U.S.
